GB201206761D0 - Anti-atherogenic peptides - Google Patents
Anti-atherogenic peptidesInfo
- Publication number
- GB201206761D0 GB201206761D0 GB201206761A GB201206761A GB201206761D0 GB 201206761 D0 GB201206761 D0 GB 201206761D0 GB 201206761 A GB201206761 A GB 201206761A GB 201206761 A GB201206761 A GB 201206761A GB 201206761 D0 GB201206761 D0 GB 201206761D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- peptides
- atherogenic
- relates
- inflammatory
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
Abstract
Theinvention relates to novel nucleic acids and peptides having anti atherogenic and/or anti-inflammatory activity. In particular, the invention relates to a combination therapy of two or more peptides for treating autoimmune disease and/or inflammatory disease. It also relates to methods of making and using such peptides, intermediates useful in the manufacture of such peptides, formulations comprising such peptides, and to other subject matter.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201206761A GB201206761D0 (en) | 2012-04-17 | 2012-04-17 | Anti-atherogenic peptides |
PCT/GB2013/050972 WO2013156771A1 (en) | 2012-04-17 | 2013-04-16 | Anti-atherogenic peptides |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201206761A GB201206761D0 (en) | 2012-04-17 | 2012-04-17 | Anti-atherogenic peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201206761D0 true GB201206761D0 (en) | 2012-05-30 |
Family
ID=46209210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB201206761A Ceased GB201206761D0 (en) | 2012-04-17 | 2012-04-17 | Anti-atherogenic peptides |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201206761D0 (en) |
WO (1) | WO2013156771A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2974884A1 (en) * | 2015-01-27 | 2016-08-04 | Thrombosis Research Institute | Multi-epitopic construct |
EP3586865A1 (en) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5480974A (en) * | 1993-06-18 | 1996-01-02 | The Scripps Research Institute | Antibodies to human C5a receptor |
WO2009125231A2 (en) * | 2008-04-10 | 2009-10-15 | Thrombosis Research Institute | Anti-atheroma vaccine |
-
2012
- 2012-04-17 GB GB201206761A patent/GB201206761D0/en not_active Ceased
-
2013
- 2013-04-16 WO PCT/GB2013/050972 patent/WO2013156771A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2013156771A1 (en) | 2013-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018016389A (en) | Compositions and methods for delivering messenger rna. | |
MX2017014908A (en) | Trispecific binding proteins and methods of use. | |
EA201591281A1 (en) | RIBONUCLEIC ACIDS WITH 4'-THIOMODIFIED NUCLEOTIDES AND RELATED METHODS | |
MX2012011771A (en) | Aptamers to î²-ngf and their use in treating î²-ngf mediated diseases and disorders. | |
WO2014145159A3 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use | |
EA201791693A1 (en) | HETERODIMERNY IMMUNOHLOBULINS | |
DK2938740T3 (en) | CHIMARY FGF19 PEPTIDES FOR USE IN THE TREATMENT OF BALIDIC ACID DISORDERS | |
WO2014096425A3 (en) | Prodrugs of monomethyl fumarate (mmf) | |
JO3462B1 (en) | Human Antibodies to GFR?3 and methods of use thereof | |
WO2014151456A3 (en) | Treatment of inflammatory diseases | |
CY1116304T1 (en) | USE OF BIOTINE FOR THERAPEUTIC TREATMENT | |
NZ616989A (en) | Therapeutic nuclease compositions and methods | |
ES2625773T3 (en) | Actinoplanes utahensis genomics | |
EP2614085A4 (en) | Anti-il-1 beta antibodies and methods of use | |
BR112013009083A8 (en) | human oncostatin m antibodies and methods of use | |
MX2013011421A (en) | Pyrazolo pyrimidine derivatives. | |
UA105073C2 (en) | Anti-fractalkine antibody, composition and method for treating inflammatory disorders | |
MX2013012791A (en) | Complement factor b analogs and their uses. | |
MX2014001766A (en) | Neuregulin antibodies and uses thereof. | |
IN2014DN03213A (en) | ||
MX357656B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases. | |
WO2013023059A3 (en) | Methods and compositions for the treatment of autoimmune and inflammatory diseases | |
MX2015016120A (en) | Binding molecules that bind human complement factor c2 and uses thereof. | |
IN2014CN00510A (en) | ||
MX2014014443A (en) | Tlr3 binding agents. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |